Abstract:Background: Until recently, the mechanism for the malignant hyperthermia crisis has been attributed solely to sustained massive Ca release from the sarcoplasmic reticulum on exposure to triggering agents. This study tested the hypothesis that transient receptor potential cation (TRPC) channels are important contributors to the Ca dyshomeostasis in a mouse model relevant to malignant hyperthermia. Methods: This study examined the mechanisms responsible for Ca dyshomeostasis in RYR1-p.G2435R mouse muscles and muscle cells using calcium and sodium ion selective microelectrodes, manganese quench of Fura2 fluorescence, and Western blots. Results: RYR1-p.G2435R mouse muscle cells have chronically elevated intracellular resting calcium and sodium and rate of manganese quench (homozygous greater than heterozygous) compared with wild-type muscles. After exposure to 1-oleoyl-2-acetyl-sn-glycerol, a TRPC3/6 activator, increases in intracellular resting calcium/sodium were significantly greater in RYR1-p.G2435R muscles (from 153 ± 11 nM/10 ± 0.5 mM to 304 ± 45 nM/14.2 ± 0.7 mM in heterozygotes P < 0.001] and from 251 ± 25 nM/13.9 ± 0.5 mM to 534 ± 64 nM/20.9 ± 1.5 mM in homozygotes [P < 0.001] compared with 123 ± 3 nM/8 ± 0.1 mM to 196 ± 27 nM/9.4 ± 0.7 mM in wild type). These increases were inhibited both by simply removing extracellular Ca and by exposure to either a nonspecific (gadolinium) or a newly available, more specific pharmacologic agent (SAR7334) to block TRPC6- and TRPC3-mediated cation influx into cells. Furthermore, local pretreatment with SAR7334 partially decreased the elevation of intracellular resting calcium that is seen in RYR1-p.G2435R muscles during exposure to halothane. Western blot analysis showed that expression of TRPC3 and TRPC6 were significantly increased in RYR1-p.G2435R muscles in a gene-dose-dependent manner, supporting their being a primary molecular basis for increased sarcolemmal cation influx. Conclusions: Muscle cells in knock-in mice expressing the RYR1-p.G2435R mutation are hypersensitive to TRPC3/6 activators. This hypersensitivity can be negated with pharmacologic agents that block TRPC3/6 activity. This reinforces the working hypothesis that transient receptor potential cation channels play a critical role in causing intracellular calcium and sodium overload in malignant hyperthermia-susceptible muscle, both at rest and during the malignant hyperthermia crisis.

A Novel Saline-Soluble, Rapidly-Metabolized RyR1 Inhibitor Rescues Volatile Anesthesia-Induced Death and Environmental Heat Stroke in a Mouse Model Relevant to Malignant Hyperthermia

A novel RyR1-selective inhibitor prevents and rescues sudden death in mouse models of malignant hyperthermia and heat stroke

Reduced Threshold for Luminal Ca2+ Activation of RyR1 Underlies a Causal Mechanism of Porcine Malignant Hyperthermia

An Advance in the study of ryanodine receptor mutations and malignant hyperthermia

Dantrolene inhibition of ryanodine receptor 1 carrying the severe malignant hyperthermia mutation Y522S visualized by cryo-EM

Characterization of a Novel Mutation in the Cardiac Ryanodine Receptor That Results in Catecholaminergic Polymorphic Ventricular Tachycardia

Enhanced Basal Activity of a Cardiac Ca2+ Release Channel (ryanodine Receptor) Mutant Associated with Ventricular Tachycardia and Sudden Death.

Loss of Luminal Ca 2+ Activation in the Cardiac Ryanodine Receptor is Associated with Ventricular Fibrillation and Sudden Death

Enhanced Store Overload–Induced Ca 2+ Release and Channel Sensitivity to Luminal Ca 2+ Activation Are Common Defects of RyR2 Mutations Linked to Ventricular Tachycardia and Sudden Death

RyR 2 Mutations Linked to Ventricular Tachycardia and Sudden Death Reduce the Threshold for Store-Overload-induced Ca 2 Release ( SOICR )

Dantrolene-induced inhibition of skeletal L-type Ca2+ current requires RyR1 expression

Structural identification of the RY12 domain of RyR1 as an ADP sensor and the target of the malignant hyperthermia therapeutic dantrolene

Impaired Interaction Between Skeletal Ryanodine Receptors In Malignant Hyperthermia

Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse.

RyR2-targeting therapy prevents left ventricular remodeling and ventricular tachycardia in post-infarction heart failure

RyR1 mutation associated with malignant hyperthermia facilitates catecholaminergic stress‐included arrhythmia via mitochondrial injury and oxidative stress (893.8)

Transient Receptor Potential Cation Channels and Calcium Dyshomeostasis in a Mouse Model Relevant to Malignant Hyperthermia

Bioenergetic Defects in Muscle Fibers of RYR1 Mutant Knock-in Mice Associated with Malignant Hyperthermia

Ryanodine receptor inhibitor dantrolene reduces hypoxic-ischemic brain injury in neonatal mice

Ryanodine Receptor Stabilization Therapy Suppresses Ca 2+ -Based Arrhythmias in a Novel Model of Metabolic HFpEF

A novel ryanodine receptor 2 inhibitor, M201‐A, enhances natriuresis, renal function and lusi‐inotropic actions: Preclinical and phase I study